Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Accumulated Depreciation
Aquestive Therapeutics Inc
Accumulated Depreciation Peer Comparison
Competitive Accumulated Depreciation Analysis
Latest Figures & CAGR of Competitors
Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Accumulated Depreciation
-$43m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Accumulated Depreciation
-$28B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accumulated Depreciation
-$4.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
Pfizer Inc
NYSE:PFE
|
Accumulated Depreciation
-$16.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Accumulated Depreciation
-$18.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accumulated Depreciation
-$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
See Also
What is Aquestive Therapeutics Inc's Accumulated Depreciation?
Accumulated Depreciation
-43m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Accumulated Depreciation amounts to -43m USD.
What is Aquestive Therapeutics Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-4%
Over the last year, the Accumulated Depreciation growth was -2%. The average annual Accumulated Depreciation growth rates for Aquestive Therapeutics Inc have been -4% over the past three years , -4% over the past five years .